Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stake Trimmed by Geode Capital Management LLC

Geode Capital Management LLC lessened its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 2.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 485,121 shares of the company’s stock after selling 13,799 shares during the quarter. Geode Capital Management LLC owned approximately 1.64% of Dianthus Therapeutics worth $13,285,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Quest Partners LLC grew its stake in Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after acquiring an additional 1,124 shares in the last quarter. Fred Alger Management LLC grew its stake in Dianthus Therapeutics by 52.5% during the 3rd quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock valued at $264,000 after acquiring an additional 3,316 shares in the last quarter. SG Americas Securities LLC grew its stake in Dianthus Therapeutics by 104.0% during the 3rd quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock valued at $242,000 after acquiring an additional 4,506 shares in the last quarter. MetLife Investment Management LLC grew its stake in Dianthus Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 13,939 shares of the company’s stock valued at $382,000 after acquiring an additional 7,854 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in Dianthus Therapeutics by 38.6% during the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock valued at $788,000 after acquiring an additional 8,473 shares in the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Wall Street Analysts Forecast Growth

DNTH has been the subject of several research reports. TD Cowen initiated coverage on Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating for the company. Oppenheimer lifted their price target on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a report on Monday, November 11th. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Monday, November 11th. Finally, Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Dianthus Therapeutics currently has a consensus rating of “Buy” and an average target price of $46.43.

Dianthus Therapeutics Stock Down 5.5 %

Shares of DNTH stock opened at $21.50 on Tuesday. Dianthus Therapeutics, Inc. has a 12 month low of $10.22 and a 12 month high of $33.77. The firm has a market cap of $636.34 million, a PE ratio of -8.60 and a beta of 1.74. The stock has a 50 day moving average of $25.23 and a 200-day moving average of $26.69.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. As a group, equities analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.